A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"

"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"

"Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine~* given 3 times weekly~* given for 4 weeks out of the 4 week cycle~* no dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified"